VKTX
Viking Therapeutics Inc (VKTX)
Healthcare • NASDAQ • $33.89-1.37%
- Symbol
- VKTX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $33.89
- Daily Change
- -1.37%
- Market Cap
- $3.87B
- Trailing P/E
- N/A
- Forward P/E
- -7.68
- 52W High
- $43.15
- 52W Low
- $22.96
- Analyst Target
- $92.39
- Dividend Yield
- N/A
- Beta
- 0.69
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in …
Company websiteResearch VKTX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.